- Home
- EDF vs ACIU Comparison
EDF vs ACIU Comparison
Compare EDF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- ACIU
- Stock Information
- Founded
- EDF 2010
- ACIU 2003
- Country
- EDF United States
- ACIU Switzerland
- Employees
- EDF N/A
- ACIU N/A
- Industry
- EDF Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- ACIU Health Care
- Exchange
- EDF Nasdaq
- ACIU Nasdaq
- Market Cap
- EDF 148.8M
- ACIU 173.7M
- IPO Year
- EDF N/A
- ACIU 2016
- Fundamental
- Price
- EDF $4.93
- ACIU $1.68
- Analyst Decision
- EDF
- ACIU Strong Buy
- Analyst Count
- EDF 0
- ACIU 2
- Target Price
- EDF N/A
- ACIU $10.00
- AVG Volume (30 Days)
- EDF 160.6K
- ACIU 133.4K
- Earning Date
- EDF 01-01-0001
- ACIU 04-30-2025
- Dividend Yield
- EDF 13.14%
- ACIU N/A
- EPS Growth
- EDF N/A
- ACIU N/A
- EPS
- EDF N/A
- ACIU N/A
- Revenue
- EDF N/A
- ACIU $32,014,254.00
- Revenue This Year
- EDF N/A
- ACIU N/A
- Revenue Next Year
- EDF N/A
- ACIU $676.94
- P/E Ratio
- EDF N/A
- ACIU N/A
- Revenue Growth
- EDF N/A
- ACIU 91.20
- 52 Week Low
- EDF $3.51
- ACIU $1.43
- 52 Week High
- EDF $5.50
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- EDF 52.63
- ACIU 46.75
- Support Level
- EDF $4.81
- ACIU $1.55
- Resistance Level
- EDF $4.92
- ACIU $1.79
- Average True Range (ATR)
- EDF 0.10
- ACIU 0.10
- MACD
- EDF 0.02
- ACIU 0.03
- Stochastic Oscillator
- EDF 64.63
- ACIU 66.67
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.